← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Flugen, Inc.
Madison, WI
$24,791,238
Total funding
9
Grants
Funding over time
peak $16.2M · FY2011–25$20M$15M$10M$5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$15,456,744 · 2
NIH$9,334,494 · 7
By mechanism
—$15,456,744 · 2
U01$3,916,610 · 1
R42$1,833,981 · 1
R44$1,489,965 · 1
SB1$1,048,815 · 1
R41$824,997 · 2
Investigators at Flugen, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2A STUDY IN HEALTHY VOLUNTEERS TO EVALUATE THE CROSS-PROTECTIVE EFFICACY OF M2SR IN AN INFLUENZA CHALLENGE MOD$15,404,360
· FY2017 · Department of the Army
Safety and Immunogenicity of H3N2 M2SR monovalent influenza vaccine in older subjects$1,311,111
U01 · FY2020 · AI
Safety and Immunogenicity of H3N2 M2SR monovalent influenza vaccine in older subjects$1,304,188
U01 · FY2022 · AI
Safety and Immunogenicity of H3N2 M2SR monovalent influenza vaccine in older subjects$1,301,311
U01 · FY2021 · AI
Restimulating memory T cell responses in elderly by a novel, live influenza vaccine$1,087,654
R42 · FY2018 · AI
Development of a novel highly effective influenza vaccine$834,285
R44 · FY2018 · AI
Restimulating memory T cell responses in elderly by a novel, live influenza vaccine$746,327
R42 · FY2017 · AI
Development of a novel highly effective influenza vaccine$655,680
R44 · FY2019 · AI
IND-enabling studies of an intranasal, single-replication M2SR influenza vaccine$349,605
SB1 · FY2023 · AI
IND-enabling studies of an intranasal, single-replication M2SR influenza vaccine$349,605
SB1 · FY2024 · AI
IND-enabling studies of an intranasal, single-replication M2SR influenza vaccine$349,605
SB1 · FY2025 · AI
Development of a novel highly effective influenza vaccine$300,000
R41 · FY2015 · AI
Development of a novel highly effective influenza vaccine$300,000
R41 · FY2014 · AI
Restimulating memory T cell responses in elderly by a novel, live influenza vaccine$224,997
R41 · FY2015 · AI
A high-growth PR8 virus for pandemic vaccine production in ST6-Vero cells$220,126
R43 · FY2012 · AI
MICRONEEDLE DEVELOPMENT FOR MULTIPLE VACCIN DELIVERY$52,384
· FY2011 · Department of Defense